Published in Medical Letter on the CDC and FDA, August 24th, 2008
"Our first successful FDA approval for our active patch transdermal system was for topical delivery of lidocaine, and we are now examining other drugs in pain management for use in our system as the next step in our market development," said Haro Hartounian, Ph D., president of Vyteris, Inc. "We believe the unique properties of several pain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.